Cerenome is trading at $1.72, up +5.18%, after announcing an in-network agreement with Florida Blue covering its CNSide tumor-cell and molecular-profile tests.
- Announced October 8, 2026, the deal adds approximately 6 million covered lives, bringing contracted payer access to approximately 164 million.
- It is the first CNSide payer agreement to include both test types. Broader market and healthcare-sector pressure do not explain the rise as well.